Moderna is the only company in its peer group burning cash at an alarming rate. Click here to read more about MRNA stock and ...

Massachusetts-based Moderna will likely be the first to manufacture a bird flu vaccine, backed by hundreds of millions in government funding. The biopharmaceutical giant is developing the vaccine as a ...

Goldman has recently reduced Moderna Inc (MRNA) stock to Neutral rating, as announced on January 29, 2025, according to Finviz. Earlier, on December 18, 2024, Argus had reduced the stock from a Buy to ...

Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product ...

We recently compiled a list of the 12 Best S&P 500 Stocks to Invest in According to Analysts. In this article, we are going ...

Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

In a report released yesterday, Courtney Breen from Bernstein maintained a Hold rating on Moderna (MRNA – Research Report), with a price target ...

The US Department of HHS is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to protect against bird flu.

Before beginning the discussion of where this company is going, let's set expectations appropriately. Moderna won't be ...

Delving into the details, we found 51% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we ...

Moderna has been testing an mRNA candidate for influenza viruses like the H5 and H7 strains that are seen as pandemic threats ...

The government wants Moderna to push forward with various bird flu vaccines as well as mRNA shots for other influenza strains ...